Opus Genetics Shares Rocket 70% on Gene Therapy Trial Success
Opus Genetics reported positive results for OPGx-BEST1 in a Phase 1/2 trial, meeting FDA endpoints and triggering a surge in stock price that highlights the market's appetite for biotech breakthroughs.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day